Cantor Fitzgerald Reiterates Overweight Rating on Mesoblast Limited (MESO)

Cantor Fitzgerald analyst Louis Chen reiterated an Overweight rating and $23.00 price target on Mesoblast Limited (NASDAQ: MESO) following encouraging early data.

The company announced that the investigator-initiated expanded access protocol using remestemcel-L for steroid-refractory chronic graft versus host disease has resulted in clinically meaningful outcomes in all three treated patients, two children and one adult, within 28 days after two infusions.

For an analyst ratings summary and ratings history on Mesoblast Limited click here. For more ratings news on Mesoblast Limited click here.

Shares of Mesoblast Limited closed at $9.34 yesterday.

You May Also Be Interested In

• Monopar Therapeutics (MNPR) PT Raised to $133 at BTIG
• UBS Upgrades Multi Commodity Exchange of India Ltd (MCX:IN) to Buy
• UBS Starts Nuvama Wealth Management (NUVAMA:IN) at Buy